The hallmark pathology for Alzheimer's disease (AD) is deposition of amyloid-β protein (Aβ) as β-amyloid senile plaques. Accumulation of high β-amyloid burden is thought to drive a succession of pathologies leading to neurodegeneration and dementia. This model is called the "Amyloid Cascade Hypothesis" (ACH) of AD. β-amyloid is generated in brain by the ordered self-assembly of Aβ into fibrils containing monomer units arranged as β-pleated sheets. Aβ fibrillization is widely viewed as an intrinsically abnormal and exclusively pathological activity. The Aβ peptide itself is most often characterized as a functionless incidental product of catabolism. However, evolutionary theory predicts negative reproductive selection pressure would rapidly eliminate a non-functional and highly pathogenic gene from the genome ([@B12]). A "Low Selection Pressure in Senescence" (LSPS) argument has frequently been proposed to explain Aβ's puzzling persistence in the human genome despite the peptide's supposed lack of a physiological function and intrinsic pathogenicity. In the LSPS model, Aβ is not purged from the human genome because AD primarily afflicts individuals over reproductive age and, therefore, there is low reproductive selective pressure for the peptide's elimination or modification. For over two decades the LSPS argument has provided support for amyloidogenesis models that ascribe amyloid generation in AD to an intrinsically abnormal propensity of Aβ for unconstrained self-association. Here, we present the first detailed evaluation of the LSPS argument. Our analysis shows the LSPS model is not consistent with modern evolutionary theory or data on the activities and genetics of Aβ. Our findings suggest Aβ persists across the vertebrate genome, not because of low reproductive selection pressure, but because the peptide increases inclusive fitness. Our analysis adds to mounting evidence suggesting an urgent need for revaluation of prevailing AD amyloidogenesis and therapeutic models that characterize Aβ as a functional less disease-causing catabolic by-product (reviewed by [@B51]). We examine how the new "Antimicrobial Protection Hypothesis" of AD ([@B51]) provides a fresh interpretation of the ACH that is consistent with preservation of Aβ in the vertebrate genome and the emerging role of innate immunity in AD etiology.

Human reproductive senescence occurs much faster than somatic aging and woman exhibit prolonged postreproductive periods that can extend to more than 30 % of normal lifespan ([@B62]). AD primarily afflicts individuals in this postreproductive period. In the LSPS model, genes mediating disease in humans are not subject to selection pressure postreproduction. However, this model does not address Aβ's persistence in non-human genomes. The Aβ sequence is ancient and highly conserved across vertebrates ([Figure 1](#F1){ref-type="fig"}; [@B38]). Recent findings suggest non-human vertebrates also suffer excessive β-amyloid deposition and Alzheimer's-like cognitive impairment in senescence ([@B55]; [@B42],[@B43]; [@B90]). However, postreproductive periods for the majority of iteroparous vertebrate species, if present at all, are less than 5% of normal lifespan and individuals continue to have offspring well into senescence ([@B28]; [@B10]; [@B18]). For some vertebrae species, reproductive success is highest among older mothers ([@B67]; [@B60]; [@B25]). Thus, for most vertebrate species reproductive selection pressure does not cease in old age when pathologies associated with Aβ expression manifest. Nonetheless, the human Aβ sequence is shared by 60--70 % of vertebrates and has been conserved across at least 400 million years ([@B38]). Aged individuals also indirectly contribute to the reproductive success of kin in several ways ([@B68]). Among social mammals, the presence of aged mothers increases the reproductive success of daughters ([@B17]; [@B36]; [@B37]). The extensive habitat knowledge accumulated by old individuals is also an important part of the survival strategy of mammals living in close kin groups ([@B47]; [@B50]). Evolutionary theory predicts functionless or harmful genes that reduce the support old mothers provide for reproduction among kin will be selected out of species genomes. However, Aβ remains widely expressed with the human sequence greater than 95 % conserved across mammals ([@B78]). Thus, the LSPS model fails to explain Aβ's remarkable evolutionary persistence among non-human vertebrates.

![Amyloid-β protein is an ancient and highly evolutionary conserved neuropepetide. Figure shows Aβ42 sequences across different vertebrate taxa. Conserved (blue) and non-conserved (red) amino acid substitutions among non-human species are highlighted. Adapted from [@B38].](fnagi-11-00070-g001){#F1}

In the LSPS argument, reproductive selection pressure is low for humans following the end of reproduction. To date, only humans, killer whales (*Orcinus orca*) and short-finned pilot whales (*Globicephala macrorhynchus*) have been found to undergo menopause ([@B44]; [@B58]). Menopause is thought to have evolved independently in humans and toothed cetaceans because of important lifestyle traits these species share, including highly social behaviors focused around family groups with elevated local relatedness, a long adolescence during which offspring learn diverse survival skills and acquire local and often highly specialized knowledge from their mothers and kin, and high maternal risk associated with birthing in old age. Ongoing debate continues to refine evolutionary theory on the origin of menopause ([@B24]; [@B10]). However, a broad consensus has emerged that postreproductive lifespan in these species increases inclusive fitness. The most widely accepted theory is known as the "Grandmother Hypothesis" (GMH) and explains menopause as an adaptation mediating extended kin networking in species for which reproduction in senescence carries high risk ([@B89]). In this model, postreproductive individuals rechannel reproductive energy and resources (including experience and knowledge) to grandoffspring. This provision of intergenerational care promotes survival of descendants and increases species evolutionary fitness. The GMH model has been confirmed in whales where postfertile females play an important role in increasing survival and reproductive success of descendants and close relatives ([@B19]; [@B5]; [@B11]). Delineating the benefits of grandparenting in human societies has proved more challenging. However, mounting data from both modern and less technological advanced societies are consistent with reproductive benefits for family groups that include grandparents ([@B23]; [@B65]; [@B69]; [@B61]; [@B35]; [@B39]; [@B13]; [@B26]). Thus, inclusive fitness theory ([@B33]) and data on human reproduction are not consistent with low evolutionary selection pressure for postreproductive individuals as posited in the LSPS model. Rather, persistence of Aβ in the human and vertebrate genomes suggests strong positive selection pressures are driving the protein's enduring and widespread evolutionary conservation.

Aβ is generated by proteolytic cleavage of the amyloid-β precursor protein (APP). Aβ generation requires the peptide's excision from APP by β-secretase (β-site APP cleaving enzyme \[BACE1\]) and a γ--secretase complex. Aβ generation has been confirmed in a range of sarcopterygians. Findings for zebrafish (*Danio rerio*) and kokanee salmon (*Oncorhynchus nerka kennerlyi*) are also consistent with generation of Aβ by teleosts ([@B41], [@B42],[@B43]; [@B54]; [@B57]; [@B63]), despite analysis suggesting fish APP lacks the classical BACE1 cleavage site found in other vertebrates ([@B52]). Thus, most vertebrates appear to actively generate Aβ from APP. Phylogenetic analysis indicates the ancestral APP/Aβ gene arose with metazoic speciation during the Ediacaran period ([@B78]). Early gene duplication lead to a family of three homologs in vertebrate species: APP, amyloid precursor-like proteins 1 (APLP1), and amyloid precursor-like proteins 2 (APLP2) ([@B86], [@B85]). The Aβ sequence is the most highly conserved domain within the vertebrate APP family ([@B78]). APLP1 and APLP2 contain homologous Aβ domains that are less evolutionarily conserved, varying between each other and across species ([@B78]). The unique conservation of the Aβ domain is consistent with an ancient and important physiological role for this peptide sequence. Aβ is part of the APP transmembrane domain. However, data suggest the apparent high evolutionary selection constraint of human Aβ is not mediated by the domains role as part of the APP holoprotein. The Aβ homolog regions in APLP1 and APLP2 are distinct from the Aβ domain in APP. Data from genetically modified cell and animal models confirm that APP, APLP1, and APLP2 share activities and have partially overlapping functions ([@B53]). In addition, murine APP contains a non-human Aβ sequence but the protein appears to retain full functionality ([@B14]; [@B31]). These data suggest the human Aβ sequence is sufficient, but not essential, for functionality of the members of the APP protein family. Thus, the evolutionary conservation of the Aβ sequence is most likely linked to the actions of the excised peptide rather than activities of the APP holoprotein. Rates of protein sequence evolution depend primarily on the level of functional constraint ([@B91]). Protein evolution models predict that optimized genes important for species fitness show high sequence stability over large evolutionary periods ([@B91]). Proteins subject to low selection pressure accumulate mutations and display genetic drift across species ([@B2]). Indeed, genetic drift mediated by low selection pressure is thought to be key for the generation of novel proteins ([@B2]). Hence, from an evolutionary perspective, high sequence conservation and persistence among vertebrates across at least 400 million years is consistent with a strong association between Aβ expression and increased species fitness. Moreover, widespread preservation of the human Aβ sequence among vertebrates ([@B38]) does not support AD amyloidosis models that characterize fibrillization as intrinsically abnormal. In contrast to prevailing AD amyloidogenesis models, intergenetic data suggest Aβ fibrillization is associated with high evolutionary selective constraint, consistent with an important beneficial role for β-amyloid generation in non-AD brain. However, until recently it has been unclear what physiological role Aβ fibrillization normally plays.

We ([@B73]; [@B34]; [@B16]), and other independent laboratories ([@B87]; [@B3], [@B4]; [@B74]), recently identified Aβ as an antimicrobial peptide (AMP). AMPs are the primary effector proteins of the innate immune system. The microbial inhibitory activities of AMPs are critically important for host immunity and they target bacteria, mycobacteria, enveloped viruses, fungi, protozoans, and, in some cases, transformed or cancerous host cells ([@B88]). However, AMP activities are not limited to antibiotic-like actions. AMPs often play multiple diverse roles in immunity. To greater or lesser extents, all of the roles Aβ plays as an AMP are likely to influence the peptide's evolutionary conservation. Germaine to AD, AMPs are potent immunomodulators ([@B75]) and are sometimes called the alarmins because of their cytokine-like proinflammatory activities. Consistent with identity as an AMP, synthetic Aβ inhibits fungal, bacterial, and viral pathogens *in vitro* ([@B73]; [@B87]; [@B3], [@B4]; [@B74]). Most recently, we have shown human Aβ expression *in vivo* protects against pathogens in transformed 3D human neuronal cell culture and transgenic *C. elegans* and AD mouse infection models, doubling host survival in some cases ([@B34]; [@B16]). Conversely, genetically modified mice lacking APP or the secretases required for Aβ generation, show attenuated infection resistance ([@B15]; [@B34]; [@B16]). Amyloid fibrils mediate the direct microbe inhibitory activities of Aβ. Aβ oligomers first bind carbohydrate moieties on microbial surfaces. Bound oligomers then provide a nidus and anchor for Aβ fibril propagation. Growing Aβ fibrils capture, agglutinate, and finally entrap microbes in a protease-resistant network of β-amyloid. In the antimicrobial Aβ fibrilization model, seeding of β-amyloid by pathogenic microorganisms is part of a protective innate immune response to infection. In AD, sustained activation of this pathway leads to amyloidosis and pathology. However, Aβ fibrilization and amyloid generation *per se* are not abnormal and mediate a protective immune pathway. This newly identified role for β-amyloid is consistent with our sequence evolution analysis that suggests Aβ fibrilization mediates beneficial immune functions. Also consistent with this emerging view of Aβ is the role peptide fibrillization plays in mediating the protective antimicrobial actions of classical AMPs, including lytic ([@B64]; [@B72]; [@B8]; [@B30]) and agglutination/entrapment ([@B81]; [@B8]; [@B79]) activities.

Findings from our phylogenetic analyses are consistent with emerging data showing a role for Aβ fibrillization pathways in innate immunity. This stands in stark contrast to prevailing models that characterize fibrilization and associated Aβ activities as intrinsically abnormal. The view that Aβ activities are abnormal arose from an early surmise about the peptide's origins that, while plausible at the time, has since proved inaccurate. Three and a half decades ago when Aβ generation was first characterized, intramembrane protein cleavage was viewed as an abnormal and exclusively disease-associated pathway ([@B32]). APP intramembrane cleavage and Aβ generation were thought limited to AD brain ([@B71]). As an abnormal catabolic product generated only under disease conditions, Aβ was presumed to lack a normal physiological function. However, intramembrane cleavage is now recognized as a normal proteolytic pathway mediating generation of diverse functional biomolecules ([@B66]). Furthermore, findings have confirmed Aβ is a widely and constitutively expressed vertebrate neuropeptide ([Figure 1](#F1){ref-type="fig"}; [@B38]; [@B78]). However, while early assumptions about Aβ's origin proved incorrect, the amyloidogenesis models they helped engender remain widely held. Moreover, the LSPS hypothesis continues to be cited in support of these longstanding amyloidogenesis models. However, as our analysis underscores, data accumulated over the last three decades is inconsistent, not only with early speculations on Aβ's origin, but also the longstanding LSPS argument.

Data are consistent with lifelong positive selection pressure mediating conservation and persistence of Aβ in the vertebrate genome. However, antagonistic pleiotropy may also play a role in the etiology of patients with high genetic risk for AD. In the antagonistic pleiotropy hypothesis, a gene beneficial to evolutionary fitness early in life may be detrimental in senescence- early benefits outweighing later costs ([@B89]). The ε4 allele (*APOE4*) of the apolipoprotein E gene is associated with enhanced β-amyloid deposition and increased AD risk ([@B76]). An antagonistic pleiotropy model has been proposed for the pathogenicity of *APOE4* in inflammation-associated late-life diseases, including AD ([@B27]), arteriosclerosis ([@B40]), multiple sclerosis ([@B7]), ischemic cerebrovascular disease ([@B46]), sleep apnea ([@B29]), and pathologies resulting from traumatic brain injury ([@B20]). *APOE* is important for immunity and genetically modified mice lacking the protein show attenuated pathogen resistance ([@B48]). All three human apoE isoforms (apoE2, apoE3, and apoE4) modulate immunity but *APOE4* carriers appear to have heightened immune responsiveness ([@B84]; [@B22]; [@B82]; [@B56]). The augmented innate immune response associated with apoE4 expression is thought to exacerbate inflammation-mediated pathologies ([@B82]; [@B9]). However, in high pathogen environments expression of apoE4 is associated with increased fertility and juvenile survival compared to *APOE2* or *APOE3* carriers ([@B59]; [@B83]; [@B49]; [@B21]; [@B80]; [@B82]). Inheritance of *APOE4* is also associated with improved cognitive function among populations with high parasite burdens ([@B1]). Thus, a "hair-trigger" immune response for *APOE4* carriers may protect against infection early in life. With regard to *APOE4's* involvement in AD, an antagonistic pleiotropy model is consistent with the recently emerged innate immune role for Aβ fibrillization pathways. In an AD antagonistic pleiotropy model, increased proclivity for β-amyloid generation may be beneficial in young individuals, providing *APOE4* carriers with a more robust protective response to neuroinfection. However, apoE4-enhanced Aβ fibrillization may also promote amyloidosis, leading to harmful AD pathology in late-life.

An antagonistic pleiotropy model for the role of apoE in AD amyloidosis is consistent with etiology data and evolutionary explanations for the protein's involvement across multiple age-dependent inflammation diseases ([@B9]). However, it is less clear if Aβ fibrillization itself should be considered as antagonistic pleiotropy independent of *APOE4*. Three decades of accumulated data link AD etiology to increased microbial burden in brain. Recent findings on the protective immune entrapment role of Aβ suggest elevated brain microbe levels may mediate AD amyloidosis. If β-amyloid is helping protect AD patients from chronic and potentially lethal neuroinfection, then amyloidosis is playing a beneficial immune role in late life and Aβ fibrillization activities do not satisfy classical criteria for antagonistic pleiotropy. Rather, this suggests a model in which β-amyloid deposition is an early innate immune response to persistent immunochallenge. We call this the "Antimicrobial Protection Hypothesis" of AD ([@B51]). Amyloid generation in the antimicrobial protection model is an immune defense pathway that entraps pathogens. Aβ fibrils generated to trap microbes also drive neuroinflammatory pathways that help fight the infection and clear β-amyloid/pathogen deposits. In AD, chronic activation of this pathway (caused by genuine infection or an incorrectly perceived immunochallenge) helps drive the tauopathy and sustained neuroinflammation pathologies that lead to neurodegeneration and dementia. This model is consistent with the ACH in which amyloid deposition drives a succession of pathologies that end in dementia. However, in this model amyloidosis is not drive by an intrinsically harmful and functionless propensity of Aβ to self-associate as in prevailing models. The potential for pathological outcomes from Aβ activities is consistent with the protective/harmful duality shown for classical AMPs and innate immune responses across multiple diseases ([@B70]). Furthermore, genetic data on the role of rare mutations in FAD are also consistent with the antimicrobial protection model. FAD mutations shift Aβ isoform ratios, leading to amyloidosis ([@B77]). Mutation-mediated changes in isoform expression among classical AMPs also mediate disease pathology. For example, inherited mutations that shift human β-defensin 1 isoform ratios enhance atopic disorders, including asthma ([@B6]). Enhanced amyloidosis associated with FAD mutations parallel the mutation-induced upregulation of innate immune pathways that mediate pathologies in inherited autoinflammatory syndromes, including Familial Mediterranean fever, TNF receptor- associated periodic syndrome, Muckle--Wells syndrome, Blau syndrome, pyogenic arthritis, pyoderma gangrenosum and acne syndrome, early-onset enterocolitis, autoinflammation and PLCγ2- associated antibody deficiency and immune dysregulation, and proteasome-associated autoinflammatory syndromes ([@B45]). The Antimicrobial Protection Hypothesis provides a framework for rational incorporation of the genetics and seemingly disparate pathologies involved in AD neurodegeneration. The new model remains broadly consistent with the ACH of AD. However, in the antimicrobial protection interpretation of ACH, the modality of Aβ's pathological actions in AD is shifted from abnormal stochastic behavior toward sustained innate immune activity. Moreover, persistence of Aβ in the human genome is not mediated by LSPS, but by the peptide's lifelong contribution to inclusive fitness.

A focus on Aβ fibrillization pathways advanced our understanding of amyloidosis early in the modern molecular/genetic era of AD research. Unfortunately, there have been few attempts in the intervening years to critically reevaluate longstanding amyloidosis models from this era in light of emerging genetic and molecular data. The LSPS argument is a conspicuous example of how seemingly plausible, but ultimately deeply flawed models can persistence in the absence of continuing critical reevaluation. Amyloidosis driven by an intrinsically and exclusively pathological Aβ peptide has been the dominant AD pathogenic model for over three decades. This characterization of Aβ has lead to an intense focus on strategies aimed at limiting or eliminating the peptide. However, to date, this therapeutic approach has been singularly unsuccessful. Prevailing Aβ pathogenesis models are reminiscent of the parable about the elephant and three self-proclaimed wise men. Each blindfolded man touched a different part of an elephant and loudly proclaimed three different, and equally wrong, assertions as to the beast's nature. Aβ activities are typically considered as discrete abnormal pathways and variously ascribed pathological roles in AD. A possible overarching physiological function for the collective activities of Aβ has rarely been considered. We believe the Antimicrobial Protection Hypothesis can provide a rational framework for incorporating seemingly independent findings on Aβ and help advance a new understanding of AD amyloidogenesis. We also believe a fuller appreciation of the ancient origin and important role Aβ fibrillization plays in immunity will prove important for the future development of effective AD treatment strategies.
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